FORM 11

NOTICE OF PROPOSED STOCK OPTION GRANT OR AMENDMENT

Name of Listed Issuer: **BioNxt Solutions Inc.** (the "Issuer").

Trading Symbol: **BNXT**

Date: **July 31, 2026**

1. New Options Granted:

Date of Grant: **July 31, 2026**

Name of Optionee	Position (Director/ Officer/ Employee/ Consultant/ Management Company	Insider Yes or No?	No. of Optioned Shares	Exercise Price	Expiry Date	No. of Options Granted in Past 12 Months
Hugh Rogers	Director/Officer	Yes	650,000	$0.33	July 31, 2031	1,000,000
Wolfgang Probst	Director/Officer	Yes	850,000	$0.33	July 31, 2031	1,400,000
P. Joseph Meagher	Director/Officer	Yes	100,000	$0.33	July 31, 2029	100,000
David Waterhouse	Director	Yes	100,000	$0.33	July 31, 2029	50,000
Christopher Ross	Consultant	No	1,150,000	$0.33	July 31, 2031	1,000,000
Wolfgang Wagner	Employee	No	350,000	$0.33	July 31, 2029	250,000
Oleksandr Zabudkin	Consultant	No	100,000	$0.33	July 31, 2029	Nil
Florian Sahr	Consultant	No	100,000	$0.33	July 31, 2029	Nil

Total Number of optioned shares proposed for acceptance: **3,400,000 Options**.

2. Other Presently Outstanding Options:

Name of Optionee	No. of Optioned Shares[(1)]	Exercise Price	Original Date of Grant	Expiry Date
Hugh Rogers	300,000	$1.25	Nov 29, 2021	Nov 29, 2026
	1,000,000	$0.50	Jan 31, 2025	Jan 31, 2030
	1,000,000	$0.63	Feb 27, 2026	Feb 27, 2031
Wolfgang Probst	1,400,000	$0.63	Feb 27, 2026	Feb 27, 2031
Christopher Ross	285,000	$0.50	Jan 31, 2025	Jan 31, 2027
	1,000,000	$0.63	Feb 27, 2026	Feb 27, 2031

P. Joseph Meagher	200,000	$1.25	Nov 29, 2021	Nov 29, 2026
	100,000	$0.63	Feb 27, 2026	Feb 27, 2031
Florian Sahr	500,000	$0.49	Dec 8, 2023	Dec 8, 2026
	150,000	$0.50	Jan 31, 2025	Jan 31, 2027
Mario Hose	50,000	$0.50	Jan 31, 2025	Jan 31, 2027
Wolfgang Wagner	250,000	$0.50	Jan 31, 2025	Jan 31, 2027
	250,000	$0.63	Feb 27, 2026	Feb 27,2031
David Waterhouse	50,000	$0.50	Jan 31, 2025	Jan 31, 2030
	50,000	$0.63	Feb 27, 2026	Feb 27,2031
Andre Will-Lauden	20,000	$0.50	Jan 31, 2025	Jan 31, 2027
	50,000	$0.63	Feb 27, 2026	Feb 27, 2028
Dieter Baur	50,000	$0.50	Jan 31, 2025	Jan 31, 2027
	50,000	$0.63	Feb 27, 2026	Feb 27, 2028
Thomas Schoetta	50,000	$0.50	Jan 31, 2025	Jan 31, 2027
Clay McMeekin	1,000,000	$0.63	Feb 27, 2026	Feb 27, 2028
Yves Toelderer	150,000	$0.50	Jan 31, 2025	Jan 31, 2027
	250,000	$0.63	Feb 27, 2026	Feb 27, 2028
Rob Grace	1,000,000	$0.88	Sept 19, 2025	Mar 22, 2027
Blaine Ruzycki	1,000,000	$0.88	Sept 19, 2025	Mar 22, 2027
TOTAL	**10,205,000**			

(1) Set out number of optioned shares for each grant with different terms.

3. Additional Information

(a) If shareholder approval was required for the grant of options (including prior approval of a stock option plan), state the date that the shareholder meeting approving the grant was or will be held.

The Option Plan was most recently approved by Shareholders at the Issuer's annual general meeting held on November 7, 2025.

(b) State the date of the news release announcing the grant of options.

July 31, 2026.

(c) State the total issued and outstanding share capital at the date of grant or amendment.

136,093,152 common shares.

(d) State, as a percentage of the issued and outstanding shares of the Issuer indicated in (c) above, the aggregate number of shares that are subject to incentive stock options, including new options, amended options and other presently outstanding options.

The aggregate number of shares subject to outstanding options is 13,605,000 equivalent to 10% of the issued and outstanding common shares.

If the new options are being granted pursuant to a stock option plan, state the number of remaining shares reserved for issuance under the plan.

The remaining number of shares reserved for issuance under the Option Plan is Nil.

(e) If the Issuer has completed a public distribution of its securities within 90 days of the date of grant, state the per share price paid by the public investors.

N/A.

(f) Describe the particulars of any proposed material changes in the affairs of the Issuer.

N/A.

4. Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.

2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.

3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).

4. All of the information in this Form 11 Notice of Proposed Stock Option Grant or Amendment is true.

Dated July 31, 2026.

Hugh Rogers
Name of Director or Senior Officer

/s/ "Hugh Rogers"
Signature

Chief Executive Officer
Official Capacity